NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019.NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as: “Light Chain Bioscience – A brand of Novimmune SA”.The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function.A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop.

Head of Translational Sciences and Non-Clinical Safety. Responsible for delivering PK-PD parameters to support development of therapeutic antibodies from preclinical to early clinical development.

Responsible for nonclinical activities for therapeutic antibodies and preclinical models of autoimmune and inflammatory diseases.

Project Management of therapeutic antibody project – supervise preclinical development including toxicology studies and non-clinical safety studies

Project management of a fully human monoclonal therapeutic antibody program

Tolerance mechanisms in Non Obese Diabetic (NOD) mice. Generated tetramers of MHC/peptide complexes to investigate T cell tolerance in the non obese diabetic mouse.

Established mouse models and reagents for the study of chemokine biology in the development of inflammation during disease progression.

Use of anti-CD40 antibodies as vaccine adjuvants